# Kyntra Bio, Inc.: financial statements, quarterly

KYNB · Nasdaq · CIK 921299 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kynb.md) · [Financials](/companies/kynb/financials.md) · [Filings](/companies/kynb/filings.md) · [Insiders](/companies/kynb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kynb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [40.1](/filings/0000950170-24-125388.md) | [(73.8) d](/filings/0000950170-25-040280.md) | [25.4](/filings/0000950170-25-069203.md) | [1.0](/filings/0000950170-25-106549.md) | [0.1](/filings/0001193125-25-274241.md) | [3.1 d](/filings/0001193125-26-108346.md) | [2.7](/filings/0001193125-26-219374.md) | [1.3](/filings/0001193125-26-349183.md) | [1.1](/filings/0001193125-25-274241.md) | [1.3 d](/filings/0001193125-26-108346.md) | [3.7](/filings/0001193125-26-219374.md) | [(1.5)](/filings/0001193125-26-349183.md) |
| Cost of revenue | $m | [4.2](/filings/0000950170-24-125388.md) | [(9.5) d](/filings/0000950170-25-040280.md) | [21.3](/filings/0000950170-25-069203.md) | [0.1](/filings/0000950170-25-106549.md) | [(0.1)](/filings/0001193125-25-274241.md) | [(5.8) d](/filings/0001193125-26-108346.md) | [0.3](/filings/0001193125-26-219374.md) | [0.1](/filings/0001193125-26-349183.md) | [(0.1)](/filings/0001193125-25-274241.md) | [0.3 d](/filings/0001193125-26-108346.md) | [4.1](/filings/0001193125-26-219374.md) | [0.0](/filings/0001193125-26-349183.md) |
| Research and development | $m | [61.2](/filings/0000950170-24-125388.md) | [35.3 d](/filings/0000950170-25-040280.md) | [36.5](/filings/0000950170-25-069203.md) | [32.4](/filings/0000950170-25-106549.md) | [20.0](/filings/0001193125-25-274241.md) | [6.9 d](/filings/0001193125-26-108346.md) | [9.2](/filings/0001193125-26-219374.md) | [5.9](/filings/0001193125-26-349183.md) | [1.2](/filings/0001193125-25-274241.md) | [7.3 d](/filings/0001193125-26-108346.md) | [7.6](/filings/0001193125-26-219374.md) | [6.8](/filings/0001193125-26-349183.md) |
| Selling, general and administrative | $m | [25.6](/filings/0000950170-24-125388.md) | [(4.5) d](/filings/0000950170-25-040280.md) | [16.7](/filings/0000950170-25-069203.md) | [14.9](/filings/0000950170-25-106549.md) | [9.4](/filings/0001193125-25-274241.md) | [8.3 d](/filings/0001193125-26-108346.md) | [8.1](/filings/0001193125-26-219374.md) | [7.1](/filings/0001193125-26-349183.md) | [5.3](/filings/0001193125-25-274241.md) | [7.3 d](/filings/0001193125-26-108346.md) | [5.9](/filings/0001193125-26-219374.md) | [9.3](/filings/0001193125-26-349183.md) |
| Operating income | $m | [(63.5)](/filings/0000950170-24-125388.md) | [(95.1) d](/filings/0000950170-25-040280.md) | [(49.2)](/filings/0000950170-25-069203.md) | [(46.4)](/filings/0000950170-25-106549.md) | [(47.7)](/filings/0001193125-25-274241.md) | [(7.1) d](/filings/0001193125-26-108346.md) | [(14.9)](/filings/0001193125-26-219374.md) | [(12.1)](/filings/0001193125-26-349183.md) | [(5.4)](/filings/0001193125-25-274241.md) | [(13.5) d](/filings/0001193125-26-108346.md) | [(13.8)](/filings/0001193125-26-219374.md) | [(17.6)](/filings/0001193125-26-349183.md) |
| Interest expense | $m | [5.0](/filings/0000950170-24-125388.md) | [(2.4) d](/filings/0000950170-25-040280.md) | [2.1](/filings/0000950170-25-069203.md) | [1.9](/filings/0000950170-25-106549.md) | [2.1](/filings/0001193125-25-274241.md) | [2.2 d](/filings/0001193125-26-108346.md) | [2.3](/filings/0001193125-26-219374.md) | [2.0](/filings/0001193125-26-349183.md) | [2.1](/filings/0001193125-25-274241.md) | [2.4 d](/filings/0001193125-26-108346.md) | [2.4](/filings/0001193125-26-219374.md) | [2.4](/filings/0001193125-26-349183.md) |
| Income tax | $m | [0.1](/filings/0000950170-24-125388.md) | [(0.2) d](/filings/0000950170-25-040280.md) | [0.0](/filings/0000950170-25-069203.md) | [(0.3)](/filings/0000950170-25-106549.md) | [0.0](/filings/0001193125-25-274241.md) | [0.0 d](/filings/0001193125-26-108346.md) | [0.0](/filings/0001193125-26-219374.md) | [(0.1)](/filings/0001193125-26-349183.md) | [0.0](/filings/0001193125-25-274241.md) | [0.0 d](/filings/0001193125-26-108346.md) | [0.0](/filings/0001193125-26-219374.md) | [(0.0)](/filings/0001193125-26-349183.md) |
| Net income | $m | [(63.6)](/filings/0000950170-24-125388.md) | [(56.2) d](/filings/0000950170-25-040280.md) | [(32.9)](/filings/0000950170-25-069203.md) | [(15.5)](/filings/0000950170-25-106549.md) | [(17.1)](/filings/0001193125-25-274241.md) | [18.0 d](/filings/0001193125-26-108346.md) | [4.6](/filings/0001193125-26-219374.md) | [(7.6)](/filings/0001193125-26-349183.md) | [201](/filings/0001193125-25-274241.md) | [(14.2) d](/filings/0001193125-26-108346.md) | [(15.2)](/filings/0001193125-26-219374.md) | [12.0](/filings/0001193125-26-349183.md) |
| Diluted EPS | $ per share | [(0.65)](/filings/0000950170-24-125388.md) | not reported | [(0.33)](/filings/0000950170-25-069203.md) | [(3.89)](/filings/0000950170-25-106549.md) | [(4.25)](/filings/0001193125-25-274241.md) | not reported | [1.15](/filings/0001193125-26-219374.md) | [(1.88)](/filings/0001193125-26-349183.md) | [49.61](/filings/0001193125-25-274241.md) | not reported | [(3.76)](/filings/0001193125-26-219374.md) | [2.96](/filings/0001193125-26-349183.md) |
| Basic EPS | $ per share | [(0.65)](/filings/0000950170-24-125388.md) | not reported | [(0.33)](/filings/0000950170-25-069203.md) | [(3.89)](/filings/0000950170-25-106549.md) | [(4.25)](/filings/0001193125-25-274241.md) | not reported | [1.15](/filings/0001193125-26-219374.md) | [(1.88)](/filings/0001193125-26-349183.md) | [49.61](/filings/0001193125-25-274241.md) | not reported | [(3.76)](/filings/0001193125-26-219374.md) | [2.96](/filings/0001193125-26-349183.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | period not labelled (2025-08-29) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [81.6](/filings/0000950170-25-040280.md) | [106](/filings/0000950170-24-053554.md) | [141](/filings/0000950170-24-091808.md) | [131](/filings/0000950170-24-125388.md) | [50.5](/filings/0001193125-26-108346.md) | [33.6](/filings/0000950170-25-069203.md) | [23.4](/filings/0000950170-25-106549.md) | not reported | [118](/filings/0001193125-25-274241.md) | [47.9](/filings/0001193125-26-349183.md) | [37.0](/filings/0001193125-26-219374.md) | [50.6](/filings/0001193125-26-349183.md) |
| Current assets | $m | [332](/filings/0000950170-25-040280.md) | [278](/filings/0000950170-24-053554.md) | [209](/filings/0000950170-24-091808.md) | [245](/filings/0000950170-24-125388.md) | [197](/filings/0001193125-26-108346.md) | [149](/filings/0000950170-25-069203.md) | [162](/filings/0000950170-25-106549.md) | not reported | [133](/filings/0001193125-25-274241.md) | [99.1](/filings/0001193125-26-349183.md) | [101](/filings/0001193125-26-219374.md) | [96.8](/filings/0001193125-26-349183.md) |
| Total assets | $m | [424](/filings/0000950170-25-040280.md) | [366](/filings/0000950170-24-053554.md) | [293](/filings/0000950170-24-091808.md) | [264](/filings/0000950170-24-125388.md) | [215](/filings/0001193125-26-108346.md) | [165](/filings/0000950170-25-069203.md) | [178](/filings/0000950170-25-106549.md) | not reported | [137](/filings/0001193125-25-274241.md) | [120](/filings/0001193125-26-349183.md) | [110](/filings/0001193125-26-219374.md) | [101](/filings/0001193125-26-349183.md) |
| Current liabilities | $m | [218](/filings/0000950170-25-040280.md) | [197](/filings/0000950170-24-053554.md) | [149](/filings/0000950170-24-091808.md) | [191](/filings/0000950170-24-125388.md) | [133](/filings/0001193125-26-108346.md) | [73.4](/filings/0000950170-25-069203.md) | [156](/filings/0000950170-25-106549.md) | not reported | [36.0](/filings/0001193125-25-274241.md) | [29.2](/filings/0001193125-26-349183.md) | [28.1](/filings/0001193125-26-219374.md) | [36.0](/filings/0001193125-26-349183.md) |
| Total liabilities | $m | [586](/filings/0000950170-25-040280.md) | [552](/filings/0000950170-24-053554.md) | [484](/filings/0000950170-24-091808.md) | [466](/filings/0000950170-24-125388.md) | [398](/filings/0001193125-26-108346.md) | [340](/filings/0000950170-25-069203.md) | [359](/filings/0000950170-25-106549.md) | not reported | [120](/filings/0001193125-25-274241.md) | [115](/filings/0001193125-26-349183.md) | [119](/filings/0001193125-26-219374.md) | [109](/filings/0001193125-26-349183.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [75.0](/filings/0001193125-26-349183.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(204)](/filings/0000950170-25-040280.md) | [(228)](/filings/0000950170-24-053554.md) | [(232)](/filings/0000950170-24-091808.md) | [(244)](/filings/0000950170-24-125388.md) | [(226)](/filings/0001193125-26-108346.md) | [(217)](/filings/0000950170-25-069203.md) | [(223)](/filings/0000950170-25-106549.md) | not reported | [(17.0)](/filings/0001193125-25-274241.md) | [(30.0)](/filings/0001193125-26-349183.md) | [(43.8)](/filings/0001193125-26-219374.md) | [(30.1)](/filings/0001193125-26-349183.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(84.5) d](/filings/0000950170-24-125388.md) | [(18.3) d](/filings/0000950170-25-040280.md) | [(59.3)](/filings/0000950170-25-069203.md) | [(39.9) d](/filings/0000950170-25-106549.md) | [(8.4) d](/filings/0001193125-25-274241.md) | [(30.5) d](/filings/0001193125-26-108346.md) | [2.7](/filings/0001193125-26-219374.md) | [12.7 d](/filings/0001193125-26-349183.md) | [(1.8) d](/filings/0001193125-25-274241.md) | [(18.3) d](/filings/0001193125-26-108346.md) | [(13.9)](/filings/0001193125-26-219374.md) | [(4.0) d](/filings/0001193125-26-349183.md) |
| Capital expenditure | $m | [0.7 d](/filings/0000950170-24-125388.md) | [0.3 d](/filings/0000950170-25-040280.md) | [0.0](/filings/0000950170-25-069203.md) | [0.0 d](/filings/0000950170-25-106549.md) | [0.1 d](/filings/0001193125-25-274241.md) | [0.1 d](/filings/0001193125-26-108346.md) | [0.0](/filings/0001193125-26-219374.md) | [0.0 d](/filings/0001193125-26-349183.md) | [0.0 d](/filings/0001193125-25-274241.md) | [0.0 d](/filings/0001193125-26-108346.md) | [0.0](/filings/0001193125-26-219374.md) | [0.0 d](/filings/0001193125-26-349183.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [93.8](/filings/0000950170-23-059394.md) | [94.7](/filings/0000950170-24-053554.md) | [97.7](/filings/0000950170-24-091808.md) | [98.2](/filings/0000950170-24-125388.md) | [99.0](/filings/0000950170-25-069203.md) | [4.0](/filings/0000950170-25-106549.md) | [4.0](/filings/0001193125-25-274241.md) | [4.0](/filings/0001193125-26-219374.md) | [4.0](/filings/0001193125-26-349183.md) | [4.0](/filings/0001193125-25-274241.md) | [4.0](/filings/0001193125-26-219374.md) | [4.0](/filings/0001193125-26-349183.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,049,124 at 2026-07-31, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349183.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.